Subscribe to RSS
DOI: 10.1055/s-0032-1312617
The Novel Phenylpropiophenone Derivates Induced Relaxation of Isolated Rat Aorta
Publication History
received 04 January 2012
accepted 23 April 2012
Publication Date:
24 May 2012 (online)
![](https://www.thieme-connect.de/media/amf/201207/lookinside/thumbnails/10.1055-s-0032-1312617-1.jpg)
Abstract
Our aim was to define how different chemical properties of newly developed phenylpropiophenone derivates (PhPds) influenced their potency and efficacy to relax rat aorta. A contribution of ion channels in the PhPds and propafenone mechanism of vasodilatation was tested. PhPds were syntethysed by substitution in the benzyl moiety with -F, -CH3 or -CF3 groups on the ortho or para position. The vasodilatation by PhPds was examined on the rings of rat aorta precontracted with phenylephrine. In order to test involvement of voltage-gated Na+ and K+ channels and L-type Ca2+ channels in a mechanism of action of PhPds, we used their blockers: lidocaine, nifedipine and 4-aminopiridine, respectively. Aorta was more sensitive to 5-ortho-trifluoromethyl derivate than to propafenone and other PhPds. The 5-para-methyl derivate had lower potency and efficacy than propafenone and other PhPds. Lidocaine did not influenced relaxation induced by PhPds, but slightly inhibited the effect of propafenone. The 4-aminopiridine only inhibited relaxation induced by 5-para-methyl derivate. Nifedipine inhibited relaxation of the rat aorta induced by 5-ortho-trifluoromethyl derivate and by propafenone. Introduction of 5-ortho-trifluoromethyl and 5-para-methyl group in the benzyl moiety of propafenone molecule changed its potency, efficacy and mechanism of action in the rat aorta. The 4-aminopiridine- and nifedipine sensitive ion channels are involved in mechanism of action of 5-para-methyl and 5-ortho-trifluoromethyl derivate. The introduction of other tested groups in the benzyl moiety does not affect pharmacological properties of the PhPds in relation to propafenone.
-
References
- 1 Baker JG, Hill SJ, Summers RJ. Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci Apr 2011; 32 (04) 227-234
- 2 Arias C, González T, Moreno I et al. Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels. Cardiovasc Res Mar 2003; 57 (03) 660-669
- 3 Brady PA. Antiarrhytmic Drugs. In: Murphy JG, Lloyd MA. (eds.). Mayo Clinic Cardiology. 3 rd ed. Mayo Clinic scientific press and informa healthcare; USA: 2007: 1205-1222
- 4 Chiba P, Burghofer S, Richter E et al. Synthesis, pharmacologic activity, and structure-activity relationships of a series of propafenone-related modulators of multidrug resistance. J Med Chem Jul 7 1995; 38 (14) 2789-2793
- 5 Pérez-Vizcaíno F, Fernández del Pozo B, Zaragozá F et al. Voltage- and time-dependent inhibitory effects on rat aortic and porcine coronary artery contraction induced by propafenone and quinidine. Br J Pharmacol Dec 1994; 113 (04) 1281-1288
- 6 Fernández del Pozo B, Pérez-Vizcaíno F, Fernández C et al. Effects of several class I antiarrhythmic drugs on isolated rat aortic vascular smooth muscle. Gen Pharmacol Oct 1997; 29 (04) 539-543
- 7 Tudini F, D’Erme E, Rinaldi E. Clinical use of a coronary dilator agent: O-(beta-diethylaminoethoxy)-phenylpropiophenone hydrochloride (L.G. 11457). Gazz Med Ital Jun 1965; 124 (06) 174-177
- 8 Kitamura S, Ishihara Y. Effect of calcium antagonist, etafenone hydrochloride, on the isolated guinea pig tracheal tissues. Arzneimittelforschung 1980; 30 (07) 1088-1091
- 9 http://www.molinspiration.com/cgi-bin/properties
- 10 http://www.netsci.org/Science/Compchem/feature12.htm
- 11 http://www.wiredchemist.com/chemistry/data
- 12 Leroux F. Atropisomerism, biphenyls, and fluorine: A comparison of rotational barriers and twist angles. Chembiochem May 2004; 5: 644-649
- 13 Arunlakshana O, Shild HO. Some quantitive uses of drug antagonists. Br J Pharmacol Chemother 1959; 14: 48-58
- 14 Ivkovic B, Sokovic M, Markovic B et al. Synthesis and evaluation of derivates of phenylpropiophenone as potential antibacterial and antifungal agents. In Mátyus P, Wölfling J. (eds.). Hungarian-Austrian-Czech-German-Greek-Italian-Polish-Slovak-Slovenian Joint Meeting on Medicinal Chemistry. 2009 June 24-27 Budapest, Hungary, Bologna: MEDIMOND; 2009
- 15 Carrón R, Pérez-Vizcaino F, Delpón E et al. Effects of propafenone on 45Ca movements and contractile responses in vascular smooth muscle. Br J Pharmacol Jun 1991; 103 (02) 1453-1457
- 16 Choby C, Mangoni ME, Boccara G et al. Evidence for tetrodotoxin-sensitive sodium currents in primary cultured myocytes from human, pig and rabbit arteries. Pflügers Arch – Eur J Physiol 2000; 440: 149-152
- 17 Tamargo J, Valenzuela C, Delpón E. New insights into the pharmacology of sodium channel blockers. Eur Heart J Nov 1992; 13 Suppl F 2-13
- 18 Hanck DA, Nikitina E, McNulty MM et al. Using Lidocaine and Benzocaine to Link Sodium Channel Molecular. Conformations to State-Dependent Antiarrhythmic Drug Affinity. Circ Res Aug 2009; 105 (05) 492-499
- 19 Matsubara T, Clarkson C, Hondeghem L. Lidocaine blocks open and inactivated cardiac sodium channels. Naunyn Schmiedebergs Arch Pharmacol Aug 1987; 336 (02) 224-231
- 20 Sheets MF, Fozzard HA, Lipkind GM et al. Sodium channel molecular conformations and antiarrhythmic drug affinity. Trends Cardiovasc Med Jan 2010; 20 (01) 16-21
- 21 Nau C, Wang GK. Interactions of local anesthetics with voltage-gated Na+channels. J Membr Biol Sep 1 2004; 201 (01) 1-8
- 22 Wulff H, Zhorov BS. K+ channel modulators for the treatment of neurological disorders and autoimmune diseases. Chem Rev May 2008; 108 (05) 1744-1773
- 23 Wilson C, Coldwell MC, Howlett DR et al. Comparative effects of K+ channel blockade on the vasorelaxant activity of cromakalim,pinacidil and nicorandil. Eur J Pharmacol Aug 2 1988; 152 (03) 331-339
- 24 Cogolludo AL, Pérez-Vizcaíno F, López-López G et al. Propafenone modulates potassium channel activities of vascular smooth muscle from rat portal veins. J Pharmacol Exp Ther Nov 2001; 299 (02) 801-810
- 25 Alexander S, Mathie PA, Peters JA. Guide to receptors and channels. 2 nd edition. Br J Pharmacol 2006; 147: S103
- 26 Smart BE. Fluorine substituent effects (on bioactivity). J Fluorine Chem Jan 2001; 109: 3-11